Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna shares have more than doubled this year on rising optimism for its pipeline, with revenue accelerating to $389M in Q1 2026 (from $108M a year earlier) while holding ~$7.5B in cash and investments. An FDA advisory committee voted 9-0 to recommend approval of its seasonal flu vaccine for adults 50+, with a final FDA decision expected in early August—an important near-term catalyst but still subject to clinical/readout risk. Management targets up to 10% revenue growth in 2026 and cash breakeven by 2028, supported by planned product launches in 2027-2028 (including flu, flu/COVID combo, and norovirus).

Analysis

The tradeable element here is not the long-dated pipeline story; it is the possibility that Moderna keeps converting from a one-product pandemic beneficiary into a repeat-launch vaccine platform. If the flu filing clears, the stock likely gets another multiple bump because investors will price a more durable revenue cadence, but the actual 2026-2027 P&L lift is still modest versus the current valuation reset. In other words, the market is likely paying today for launches that mostly matter in 12-24 months, not for next quarter.

The bigger second-order risk is that approval does not equal commercial adoption. Flu is a crowded, switching-cost-heavy market dominated by entrenched incumbents, so early share gains may be slow and margin-accretive only after manufacturing leverage kicks in. That means any post-approval rally could fade if sell-through, payer access, or physician uptake disappoints; the first real test is not the FDA decision but the first seasonal guidance update and 2026 revenue trajectory.

On the beneficiary side, Merck gets a free option on the oncology platform, but the market should treat that as a scientific call option, not a near-term earnings driver. The contrarian view is that the move is already somewhat ahead of fundamentals: Moderna can look like a diversified biotech on slides while still behaving like a cash-burning development company in practice. The stock is most vulnerable if any late-stage readout disappoints or if management has to walk back the 2028 breakeven narrative.

Key Decisions for Investors

• Do not chase MRNA into the FDA decision; wait for the event and buy only on a post-approval pullback if the label is broad enough to support meaningful uptake. Risk/reward is better after volatility compresses than ahead of it.
• For existing MRNA longs, sell 1- to 3-month OTM calls into any approval-driven spike. The near-term catalyst is binary, but the fundamental cash-flow inflection is still 12-24 months away, so upside is likely to come in steps rather than a straight line.
• Put MRK on a watchlist, not an outright buy, for any upcoming melanoma or personalized vaccine data. If clinical readouts show a clear survival signal, MRK can earn a small multiple premium; if not, the partnership stays strategically interesting but financially immaterial.
• Relative-value idea: long MRNA vs. short a basket of mature vaccine/biopharma names only after commercial traction is visible. Until then, the cleaner expression is to wait rather than force a pair on low-conviction adoption assumptions.
• Falsifier to the bullish pipeline thesis: any delay, narrow label, or soft 2026 revenue guide that suggests the 2028 breakeven target is slipping. That would likely trigger a rapid de-rating because the stock has already rerated on forward optionality.